

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035030 A2

(51) International Patent Classification⁷: **A61K 31/00**

F-68220 Folgensbourg (FR). SPILLMANN, Adrian, A.
[CH/CH]; Blauensteinstrasse 33, CH-4053 Basel (CH).

(21) International Application Number:
PCT/EP2003/011498

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intel-
lectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 16 October 2003 (16.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0224198.2 17 October 2002 (17.10.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ,
TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): NO-
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

Published:

— without international search report and to be republished
upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CRAWLEY,
Patrick, Edward [GB/FR]; Rue de Hagenthal 23,

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: ORGANIC COMPOUNDS

(57) Abstract: A pharmaceutical composition for treatment of pain, comprises in combination a benzothiadiazole derivative as defined and a COX-2 inhibitor for simultaneous, sequential or separate use. Also provided is a method of treating a patient suffering from pain, comprising administering to the patient an effective amount of a benzothiadiazole derivative as defined and an effective amount of a COX-2 inhibitor.

WO 2004/035030 A2